Published

Cardiovascular safety of psychedelic medicine: current status and future directions.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Pharmacological reports: PR
Date: 2023-12-01
Source: PubMed
DOI: 10.1007/s43440-023-00539-4
PubMed: 37874530

Authors

Wsół A

Watch author

Derived topics and classifications

psilocybin Depression Anxiety End-of-Life Distress Receptor Pharmacology Microdosing Clinical Trial Review Article Safety Toxicity Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 7 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Cardiovascular safety of psilocybin in psychiatric practice: a narrative review2026-08-01 In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin2026-08-01 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine2026-05-01 Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy2026-03-01 Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice2025-07-06 Cardiovascular safety of psychedelic medicine: current status and future directions.2023-12-01

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24